The Chinese-German Journal of Clinical Oncology

, Volume 1, Issue 3, pp 159–162 | Cite as

Percutaneous radiofrequency ablation for hepatic malignancies

  • Zhang Zhijian 
  • Wu Mengchao 
  • Chen Han 
Original Articles



To study the therapeutic efficay of percutaneous radiofrequency ablation (PRFA) for hepatic malignancies and to define its indications and its criteria of the curative effect.


In 100 patients with histologically or clinically confirmed hepatocellular carcinoma (HCC) or liver metastases we performed PRFA under ultrasound guidance using LeVeen multipolar array needle electrode and RF 2000 generator. All patients were followed to identify complications and to assess treatment response.


PRFA was performed in 76 patients with HCC and in 24 with liver metastases. The Alpha-fetoprotein (AFP) levels of the AFP positive HCC patients with inoperable small HCCs decreased to normal in 75.0% (21/28) and decreased markedly in 21.4% (6/28). Complete necrosis of small hepatic malignancies, documented by magnetic resonance imaging (MRI) was achieved in 85.9% (61/71). If the tumor shows iso-or hyper-intensity on T1-weighted images, and relative hypointensity on T2-weighted images, and no enhanced intensity on dynamic contrast-enhanced MR imaging, it is considered completely coagulated.


PRFA is a novel local thermal palliative therapy for small hepatic malignancies that is minimally invasive, safe and effective. In patients with large lesions it can be combined with transarterial chemoembolization (TACE). Critera for curative treatment are normalization of serum AFP and/or MRI or CT scan findings showing complete necrosis.

Key words

neoplasm iiver surgery radiofrequency magnetic resonance imaging 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Tsuzuki T, Sugioka A, Ueda M. Hepatic resection for hepatocellular carcinoma. Surgery, 1990, 107: 511–520.PubMedGoogle Scholar
  2. 2.
    Liver Cancer Study Group of Japan. Primary liver cancer in Japan: clinicopathologic features and results of surgical treatment. Ann Surg, 1990, 211: 277–284.Google Scholar
  3. 3.
    Choi TK, Lai Edward CS, Fan ST, et al. Results of surgical resection for hepatocellular carcinoma. Hepatogastroenterology, 1990, 37: 172–175.PubMedGoogle Scholar
  4. 4.
    Rossi S, DiStasi M, Buscarini E, et al. Percutaneous RF interstitial thernal ablation in the treatment of hepatic cancer. AJR, 1996, 167: 759–768.CrossRefPubMedGoogle Scholar
  5. 5.
    Solbiati L, Ierace T, Goldberg SN, et al. Percutaneous US-guided RF tissue ablation of liver metastases: long-term follow up. Radiology, 1997, 202: 205–210.CrossRefPubMedGoogle Scholar
  6. 6.
    Goldberg SN, Gazelle GS, Solbiati L, et al. Ablation of liver tumors using percutaneous RF therapy. AJR, 1998, 170: 1023–1028.CrossRefPubMedGoogle Scholar
  7. 7.
    Curley SA, Izzo F, Delrio P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic maliganancies. Ann Surg, 1999, 230: 1–8.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Rose DM, Allegra DP, Bostick PJ, et al. Radiofrequency ablation: a novel primary and adjunctive ablative technique for hepatic malignancies. Am Surg, 1999, 65: 1009–1014.PubMedGoogle Scholar
  9. 9.
    Zhang ZJ, Liu Q, He J, et al. The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma. Cancer, 2000, 89: 2606–2612.CrossRefPubMedGoogle Scholar

Copyright information

© Editorial Office of The Chinese-German Journal of Clinical Oncology 2002

Authors and Affiliations

  1. 1.Eastern Hepatobiliary Surgery HospitalSecond Military Medical UniversityShanghaiChina

Personalised recommendations